futibatinib + binimetinib

Futibatinib is a highly selective, irreversible small molecule kinase inhibitor targeting fibroblast growth factor receptors FGFR1, FGFR2, FGFR3, and FGFR4. It covalently binds to the ATP-binding pocket of these receptors and blocks their phosphorylation and downstream signaling pathways (including MAPK/ERK, PI3K/Akt/mTOR), leading to decreased cell viability in cancer cells with FGFR alterations such as fusions or mutations. Futibatinib is approved for previously treated adults with unresectable or metastatic intrahepatic cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement[1][5][7][8]. Binimetinib is a potent and selective oral inhibitor of mitogen-activated protein kinase kinase 1/2 (MEK1/2), which are key kinases in the RAS/RAF/MEK/ERK pathway. By inhibiting MEK1/2 activity, binimetinib prevents activation of downstream effectors involved in tumor cell proliferation and survival[4]. Binimetinib is approved for use (as Mektovi) in combination with encorafenib for unresectable or metastatic melanoma with BRAF V600E/K mutations[4]. The combination of futibatinib plus binimetinib has demonstrated enhanced anti-tumor efficacy in preclinical models—particularly those driven by aberrant FGFR signaling—by simultaneously blocking both upstream receptor tyrosine kinase activity (FGFR) and downstream MAPK pathway signaling (MEK)[6].